Core Viewpoint - The company is focusing on the GLP-1 target in the fields of weight loss and diabetes treatment, developing a differentiated product pipeline that includes both innovative drugs and biosimilars [2] Group 1: Product Pipeline - The company has established a diverse product pipeline that includes long-acting and multi-target global innovative drugs and biosimilars [2] - Currently marketed products include liraglutide injection, while in-development products include semaglutide injection, oral small molecule agonist HDM1002, compound oral formulation HDM1010, dual-target agonist HDM1005, and long-acting tri-target agonist DR10624 [2]